How the next generation of AI is reshaping antibody drug discovery

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called 'Machine learning: developing next generation antibody therapeutics'. Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. The second article is called 'The next generation of AI'. In the piece, DDW Editor Reece Armstrong speaks to Sean McClain, Founder & CEO of Absci, about the rise of generative AI in life sciences. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.